01
May

Teva announced that its abuse-resistant version of extended-release hydrocodone–the opioid CEP-33237–aced a pivotal Phase III. Unsurprisingly, the pain drug beat out a placebo in the chronic back pain study, which sets the stage for a new drug application for later in the year. Purdue Pharma, meanwhile, has already raced to the FDA with its own tamper-resistant version of hydrocodone.

…read more

Source: Amid Zohydro controversy, Teva, Purdue and Pfizer race ahead with new pain drugs

    

0 No comments